Latest Insider Transactions at Sc Pharmaceuticals Inc. (SCPH)
This section provides a real-time view of insider transactions for Sc Pharmaceuticals Inc. (SCPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of scPharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of scPharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 26
2024
|
Leonard D Schaeffer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,347
+9.93%
|
$22,694
$2.52 P/Share
|
|
Aug 13
2024
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+7.75%
|
$2,000,000
$4.0 P/Share
|
|
Aug 06
2024
|
Rachael Nokes CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,445
+12.54%
|
-
|
|
Jan 18
2024
|
John H Tucker President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
113,560
+30.88%
|
-
|
|
Jan 18
2024
|
Rachael Nokes CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
41,840
+40.14%
|
-
|
|
Jan 02
2024
|
Rachael Nokes CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,027
-4.76%
|
$6,162
$6.39 P/Share
|
|
Jan 02
2024
|
John H Tucker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,942
-3.39%
|
$29,652
$6.39 P/Share
|
|
Jan 19
2023
|
Rachael Nokes CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+35.14%
|
$70,200
$6.14 P/Share
|
|
Jan 19
2023
|
John H Tucker President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,665
+31.41%
|
$399,990
$6.14 P/Share
|
|
Nov 25
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
762,380
+12.52%
|
$3,811,900
$5.25 P/Share
|
|
Oct 10
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
562,466
-17.15%
|
$2,249,864
$4.09 P/Share
|
|
Oct 07
2022
|
John H Tucker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,288
-11.53%
|
$41,152
$4.98 P/Share
|
|
Oct 07
2022
|
John H Tucker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,250
+32.14%
|
-
|
|
Oct 06
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
37,534
-1.13%
|
$187,670
$5.02 P/Share
|
|
Sep 07
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
200,000
-5.66%
|
$800,000
$4.75 P/Share
|
|
Sep 06
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,622
-0.75%
|
$133,110
$5.52 P/Share
|
|
Apr 11
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
270,000
-7.05%
|
$1,350,000
$5.0 P/Share
|
|
Dec 03
2021
|
John H Tucker President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+17.56%
|
$30,000
$3.96 P/Share
|
|
Dec 03
2021
|
Jack A. Khattar |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.91 P/Share
|
|
Mar 15
2021
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
110,588
-3.9%
|
$774,116
$7.03 P/Share
|
|
Mar 12
2021
|
Ra Capital Management, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
39,469
-1.37%
|
$276,283
$7.22 P/Share
|
|
Feb 25
2021
|
Rachael Nokes CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,976
-16.65%
|
$13,832
$7.27 P/Share
|
|
May 21
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,387,283
+35.1%
|
$11,098,264
$8.65 P/Share
|
|
Feb 25
2020
|
Rachael Nokes CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,981
-14.3%
|
$19,810
$10.09 P/Share
|
|
Feb 14
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
271,993
+7.73%
|
$2,175,944
$8.2 P/Share
|
|
Apr 11
2019
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
389,862
+10.72%
|
$779,724
$2.7 P/Share
|
|
Nov 21
2017
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
833,333
+19.64%
|
$11,666,662
$14.0 P/Share
|
|
Nov 21
2017
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,576,532
+50.0%
|
-
|